Related Experiment Video
Updated: Feb 14, 2026
Measuring Active and Passive Tameness Separately in Mice
Published on: August 10, 2018
Taming the Notch Transcriptional Regulator for Cancer Therapy
Luca Tamagnone1,2, Serena Zacchigna3,4, Michael Rehman5
1Laboratory of Cancer Cell Biology, Candiolo Cancer Institute-FPO, IRCCS, Str. Prov. 142, 10060 Candiolo, TO, Italy. luca.tamagnone@ircc.it.
Abstract:
Abstract Notch signaling is a highly conserved pathway in all metazoans, which is deeply involved in the regulation of cell fate and differentiation, proliferation and migration during development. Research in the last decades has shown that the various components of the Notch signaling cascade are either upregulated or activated in human cancers. Therefore, its downregulation stands as a promising and powerful strategy for cancer therapy. Here, we discuss the recent advances in the development of small molecule inhibitors, blocking antibodies and oligonucleotides that hinder Notch activity, and their outcome in clinical trials. Although Notch was initially identified as an oncogene, later studies showed that it can also act as a tumor suppressor in certain contexts. Further complexity is added by the existence of numerous Notch family members, which exert different activities and can be differentially targeted by inhibitors, potentially accounting for contradictory data on their therapeutic efficacy. Notably, recent evidence supports the rationale for combinatorial treatments including Notch inhibitors, which appear to be more effective than single agents in fighting cancer.
Insights
Notch signaling, crucial for development, is implicated in cancer. Inhibiting this pathway shows promise for cancer therapy, with combination treatments being particularly effective.
Area of Science:
- Molecular Biology
- Developmental Biology
- Cancer Research
Background:
- Notch signaling is a conserved pathway regulating cell fate, proliferation, and migration.
- Components of the Notch pathway are frequently dysregulated in human cancers.
- The dual role of Notch as an oncogene and tumor suppressor adds complexity to its therapeutic targeting.
Purpose of the Study:
- To review recent advances in developing Notch inhibitors for cancer therapy.
- To discuss the outcomes of clinical trials involving Notch-targeted agents.
- To explore the potential of combinatorial treatments for enhanced efficacy.
Main Methods:
- Development of small molecule inhibitors targeting Notch activity.
- Design of blocking antibodies to impede Notch signaling.
- Application of oligonucleotides to downregulate Notch components.
- Analysis of clinical trial data for Notch-inhibitor therapies.
Main Results:
- Various Notch inhibitors, including small molecules, antibodies, and oligonucleotides, have been developed.
- Clinical trials have shown varying efficacy, influenced by the specific Notch family members targeted.
- Combinatorial therapies involving Notch inhibitors demonstrate superior outcomes compared to single-agent treatments.
Conclusions:
- Downregulating Notch signaling is a viable cancer therapeutic strategy.
- Targeting specific Notch family members requires careful consideration due to their diverse roles.
- Combined therapeutic approaches hold significant promise for improving cancer treatment outcomes.
More Related Videos
Related Concept Videos
02:23Master Transcription Regulators
02:23Master Transcription Regulators
02:13Cooperative Binding of Transcription Regulators
02:13Cooperative Binding of Transcription Regulators
01:23Transcriptional Regulation: Riboswitches
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...